var data={"title":"Danazol: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Danazol: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5975?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=danazol-drug-information\" class=\"drug drug_general\">see &quot;Danazol: Drug information&quot;</a> and <a href=\"topic.htm?path=danazol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Danazol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708691\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Thromboembolic events:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-4em;margin-left:4em;\">Thromboembolism, thrombotic and thrombophlebitic events, including sagittal sinus thrombosis and life-threatening or fatal strokes have been reported.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pregnancy: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Use of danazol in pregnancy is contraindicated. A sensitive test (eg, beta subunit test if available) capable of determining early pregnancy is recommended immediately prior to start of therapy. Additionally, a nonhormonal method of contraception should be used during therapy. If a patient becomes pregnant while taking danazol, discontinue administration of the drug and apprise the patient of the potential risk to the fetus. Exposure to danazol in utero may result in androgenic effects on the female fetus; reports of clitoral hypertrophy, labial fusion, urogenital sinus defect, vaginal atresia, and ambiguous genitalia have been received.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatic effects: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Experience with long-term therapy with danazol is limited. Peliosis hepatis and benign hepatic adenoma have been observed with long-term use. Peliosis hepatis and hepatic adenoma may be silent until complicated by acute, potentially life-threatening intra-abdominal hemorrhage. Therefore, alert the physician to this possibility. Attempts should be made to determine the lowest dose that will provide adequate protection. If danazol was begun at a time of exacerbation of hereditary angioneurotic edema due to trauma, stress or other cause, periodic attempts to decrease or withdraw therapy should be considered.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Intracranial hypertension: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Danazol has been associated with several cases of benign intracranial hypertension also known as pseudotumor cerebri. Early signs and symptoms of benign intracranial hypertension include papilledema, headache, nausea and vomiting, and visual disturbances. Screen patients with these symptoms for papilledema and, if present, advise the patients to discontinue danazol immediately and refer them to a neurologist for further diagnosis and care.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156636\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cyclomen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057632\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Androgen</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057624\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=danazol-drug-information\" class=\"drug drug_general\">see &quot;Danazol: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Hereditary angioedema </b>(Zuraw 2013b)<b>: Note: </b>Not a preferred agent. Limited data available: Adolescents &ge;16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Short-term prophylaxis (for patient-specific triggers, medical and dental procedures)</i>: Oral: 2.5 to 10 mg/kg/day divided into 3 doses; maximum daily dose: 600 mg/<b>day</b>; begin at least 5 days prior and continue for 2 to 5 days post-procedure (Farkas 2017; JTFPP [Zuraw 2013a]; WAO [Craig 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Long-term prophylaxis</i>: Oral: Initial: 2.5 mg/kg/day; maximum initial daily dose: 50 mg/<b>day</b>; increase slowly every 2 weeks until symptoms controlled, maximum tolerated or maximum recommended dose is reached; maximum daily dose: 5 mg/kg/<b>day</b> up to 200 mg/<b>day.</b> Once control is obtained, reduce interval to every other day or every third day; maximum dose: 100 mg/dose (Farkas 2017; WAO [Craig 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note: </b>Endometriosis and fibrocystic breast disease: Initiate therapy during menstruation or ensure patient is not pregnant while on therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endometriosis (females):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild disease: Initial: 200 to 400 mg/day in 2 divided doses; gradually titrate dosage downward to maintain amenorrhea; continue (uninterrupted) for 3 to 6 months (may extend up to 9 months). If symptoms recur following discontinuation, may reinitiate treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate to severe disease or infertility: Initial: 800 mg/day in 2 divided doses; gradually titrate dosage downward to maintain amenorrhea; continue (uninterrupted) for 3 to 6 months (may extend up to 9 months). If symptoms recur following discontinuation, may reinitiate treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Fibrocystic breast disease (females):</b> Oral: Range: 100 to 400 mg/day in 2 divided doses. If symptoms recur following discontinuation, may reinitiate treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hereditary angioedema (males/females):</b> Oral: Initial: 200 mg 2 to 3 times/day; after favorable initial response, decrease the dosage by 50% or less at intervals of 1 to 3 months or longer if the frequency of attacks dictates. If an attack occurs, increase the dosage by up to 200 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>Use is contraindicated in patients with markedly impaired renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>Use is contraindicated in patients with markedly impaired hepatic function.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156615\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg, 100 mg, 200 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156600\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057635\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer consistently with regards to food; either always administer with food or administer on an empty stomach</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156629\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057634\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of endometriosis amenable to hormonal management; management of symptoms (pain, tenderness, nodularity) of fibrocystic breast disease which are not reduced by simple measures (including padded brassieres and analgesics) and require suppression of ovarian function; prevention of attacks of hereditary angioedema of all types (cutaneous, abdominal, laryngeal) in males and females (All indications: FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156684\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Danazol may be confused with Dantrium</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156683\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Edema, flushing, hypertension, myocardial infarction, palpitations, syncope, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Depression, dizziness, emotional lability, fatigue, headache, nervousness, paresthesia, sleep disorder, voice disorder (deepening of the voice, hoarseness, instability, sore throat)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris, alopecia, diaphoresis, maculopapular rash, papular rash, pruritus, seborrhea, urticaria, vesicular eruption</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Amenorrhea (may continue post-therapy), change in libido, decreased glucose tolerance (and glucagon changes), decreased HDL cholesterol, decreased thyroxine binding globulin, hirsutism (mild), increased LDL cholesterol, increased thyroxine binding globulin, menstrual disease (altered timing of cycle, spotting), weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Constipation, gastroenteritis, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Asthenospermia, breast atrophy, decreased ejaculate volume, hematuria, inhibition of spermatogenesis, spermatozoa disorder (changes in sperm count and semen viscosity), vaginal dryness, vaginal irritation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Abnormal erythrocytes (increased), decreased sex hormone binding globulin, eosinophilia, increased sex hormone-binding globulin, leukocytosis, leukopenia, malignant neoplasm (after prolonged use), petechial rash, polycythemia, purpuric rash, thrombocythemia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Cholestatic jaundice, hepatic adenoma, hepatic neoplasm (malignant; after prolonged use), increased liver enzymes, jaundice, peliosis hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Ankylosing spondylitis, arthralgia, back pain, increased creatine phosphokinase, joint swelling, limb pain, muscle cramps, muscle spasm, neck pain, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Interstitial pneumonitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anxiety, carpal tunnel syndrome, cataract, change in appetite, chills, clitoromegaly, convulsions, erythema multiforme, fever, gingival hemorrhage, Guillain-Barre syndrome, hepatotoxicity (idiosyncratic) (Chalasani 2014), nasal congestion, nipple discharge, pancreatitis, pelvic pain, pseudotumor cerebri, purpura (splenic peliosis), skin photosensitivity, Stevens-Johnson syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156619\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to danazol or any component of the formulation; undiagnosed abnormal genital bleeding; pregnancy; breast-feeding; porphyria; markedly impaired hepatic, renal, or cardiac function; androgen-dependent tumor; active or history of thrombosis or thromboembolic disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Genital neoplasia; concomitant administration with simvastatin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156604\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Androgenic effects: May cause nonreversible androgenic effects. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Blood lipid changes: Anabolic steroids may cause blood lipid changes (decreased high density lipoproteins and increased low density lipoproteins) with increased risk of arteriosclerosis and coronary artery disease. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatotoxicity: <b>[US Boxed Warning]: Peliosis hepatis and benign hepatic adenoma have been reported with long-term use. Peliosis hepatis and hepatic adenoma may be silent until complicated by acute, potentially life-threatening intraabdominal hemorrhage. Use the lowest effective dose. When used for hereditary angioneurotic edema, if danazol was initiated during an exacerbation due to trauma, stress or other cause, consider periodic attempts to decrease or withdraw therapy.</b> Monitor liver function tests and monitor closely for potential hepatotoxicity during therapy. Use is contraindicated in patients with marked hepatic impairment. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Intracranial hypertension: <b>[US Boxed Warning]: Danazol is associated with cases of benign intracranial hypertension (also known as pseudotumor cerebri). Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances. Monitor for symptoms; if symptoms occur, screen for papilledema. Discontinue immediately and refer for neurology care if papilledema is present.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thromboembolic events:<b> [US Boxed Warning]: Thromboembolism, thrombotic, and thrombophlebitic events have been reported (including sagittal sinus thrombosis and life-threatening or fatal strokes). </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; insulin requirements may be increased; monitor carefully. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal impairment); danazol may cause fluid retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fibrocystic breast disease: Breast cancer should be ruled out prior to treatment for fibrocystic breast disease, and if fibrocystic nodules persist or enlarge during danazol treatment. The onset of relief of pain and tenderness is 1 month and symptoms are typically relieved within 2 to 3 months of treatment initiation; elimination of nodularity usually requires 4 to 6 months of continuous therapy. Symptoms of fibrocystic breast disease may recur within 1 year following discontinuation of therapy. Ovulation may not be suppressed at doses used for fibrocystic disease, therefore nonhormonal contraception is recommended. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Porphyria: May cause exacerbations of acute intermittent porphyria; use is contraindicated in patients with porphyria.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pregnancy: <b>[US Boxed Warning]: Danazol use is contraindicated in pregnancy. Pregnancy should be ruled out immediately prior to starting treatment using a sensitive test (eg, beta subunit test if available) capable of determining early pregnancy. A nonhormonal method of contraception should also be used during therapy. If a patient becomes pregnant during danazol treatment, discontinue danazol and apprise the patient of the potential risk to the fetus. Exposure to danazol in utero may result in androgenic effects on the female fetus; reports of clitoral hypertrophy, labial fusion, urogenital sinus defect, vaginal atresia, and ambiguous genitalia have been received.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50586771\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Due to irreversible androgenic side effects, danazol should not be used in prepubescent pediatric patients and exposure in adolescents should be limited; in adolescents, assess risk vs benefits; monitor patients closely (Laufer 2008; WAO [Craig 2012]; Zuraw 2013b).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156674\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP3A4 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156608\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13199&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: Androgens may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">C1 inhibitors: Androgens may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: Danazol may decrease the metabolism of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the fluid-retaining effect of Androgens.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HMG-CoA Reductase Inhibitors (Statins): Danazol may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).  Management: Concurrent use of simvastatin with danazol is contraindicated. Do not exceed 20 mg per day of lovastatin if combined with danazol. Fluvastatin, pravastatin, and rosuvastatin may pose lower risk.<b> Exceptions: </b>Fluvastatin; Pitavastatin; Pravastatin; Rosuvastatin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simvastatin: Danazol may increase the serum concentration of Simvastatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Danazol may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): Danazol may increase the serum concentration of Tacrolimus (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: Danazol may enhance the hypercalcemic effect of Vitamin D Analogs. <b> Exceptions: </b>Calcipotriene; Calcitriol (Topical); Tacalcitol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156630\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food delays time to peak levels. A high-fat meal increases plasma concentration and extent of availability.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156611\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156622\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: Danazol use is contraindicated in pregnancy. Pregnancy should be ruled out immediately prior to starting treatment using a sensitive test (eg, beta subunit test if available) capable of determining early pregnancy. A nonhormonal method of contraception should also be used during therapy. If a patient becomes pregnant during danazol treatment, discontinue danazol and apprise the patient of the potential risk to the fetus. Exposure to danazol in utero may result in androgenic effects on the female fetus; reports of clitoral hypertrophy, labial fusion, urogenital sinus defect, vaginal atresia, and ambiguous genitalia have been received.</b> Therapy should be discontinued for 2 months prior to attempting pregnancy (Caballero 2012). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057631\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests, symptomatology and site of disease; serum glucose (if diabetic); HDL and LDL cholesterol; signs and symptoms of pseudotumor cerebri; androgenic effects</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Hereditary angioedema, long-term prophylaxis: CBC, urinalysis, liver function test and lipid profile (baseline, every 6 months while on therapy and 6 months after discontinuation); liver ultrasound (baseline and annually); blood pressure (every 6 months) (WAO [Craig 2012])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156603\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Suppresses pituitary output of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), resulting in regression and atrophy of normal and ectopic endometrial tissue; decreases rate of growth of abnormal breast tissue; reduces attacks associated with hereditary angioedema by increasing levels of C4 component of complement </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156618\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fibrocystic breast disease: Onset of pain/tenderness relief: 1 month (usually significantly relieved at 2 to 3 months); nodule elimination: 4 to 6 months  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immune thrombocytopenia (off-label use): Initial response: 14 to 90 days; Peak response: 28 to 180 days (Neunert 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic, primarily to 2-hydroxymethyl danazol and ethisterone </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~10 hours (variable; up to 24 hours following long-term use for endometriosis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 4 hours (range: 2 to 8 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine and feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156621\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Danazol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $362.73</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $544.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $617.23</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156623\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anargil (LK, MY, SK, TH, TR, VN);</li>\n      <li>Azol (AU, ID, TW);</li>\n      <li>Cipladanogen (CO);</li>\n      <li>Cyclolady (TW);</li>\n      <li>D-Zol (NZ);</li>\n      <li>Dana (BD);</li>\n      <li>Danamet (BD);</li>\n      <li>Danarem (VN);</li>\n      <li>Danasin (TR);</li>\n      <li>Danatrol (BE, CH, ES, FR, GR, IT, LU, NL, PT);</li>\n      <li>Danazol (KR, PL);</li>\n      <li>Danazol Jean Marie (HK);</li>\n      <li>Danazol-ratiopharm (DE);</li>\n      <li>Danocil (KR);</li>\n      <li>Danocrine (BB, BM, BS, BZ, DK, FI, GY, HK, ID, JM, NO, PK, SE, SR, TT);</li>\n      <li>Danodiol (AE, BB, BH, BM, BS, BZ, CY, EC, GH, GY, IL, JM, JO, KE, LB, LY, MU, OM, PR, QA, SA, SR, SY, TT, TZ, YE);</li>\n      <li>Danogar (CL);</li>\n      <li>Danogen (IN, LK);</li>\n      <li>Danokrin (AT);</li>\n      <li>Danol (AE, BH, CY, EE, EG, GB, IE, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Danoval (BG, CZ, HR, HU, PL, RU);</li>\n      <li>Dazol (BD);</li>\n      <li>Dorink (TW);</li>\n      <li>Ectopal (TH);</li>\n      <li>Elle (PH);</li>\n      <li>Gonablok (IN);</li>\n      <li>Gong Fu Yi Kang (CN);</li>\n      <li>Kupdina (VN);</li>\n      <li>Ladazol (ZA);</li>\n      <li>Ladogal (AR, BR, CR, CU, DO, GT, HN, MX, MY, NI, PA, PE, PH, SV, TH, TW, UY, VE);</li>\n      <li>Lozana (BD);</li>\n      <li>Mastodanatrol (PT);</li>\n      <li>Nazol (MY, SG);</li>\n      <li>Novaprin (MX);</li>\n      <li>Vabon (TH);</li>\n      <li>Winobanin (DE);</li>\n      <li>Zendol (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Caballero T, Farkas H, Bouillet L, et al, &quot;International Consensus and Practical Guidelines on the Gynecologic and Obstetric Management of Female Patients With Hereditary Angioedema Caused by C1 Inhibitor Deficiency,&quot; <i>J Allergy Clin Immunol</i>, 2012, 129(2):308-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/danazol-pediatric-drug-information/abstract-text/22197274/pubmed\" target=\"_blank\" id=\"22197274\">22197274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Craig T, Ayg&ouml;ren-P&uuml;rs&uuml;n E, Bork K, et al. WAO guideline for the management of hereditary angioedema. <i>World Allergy Organ J</i>. 2012;5(12):182-199.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/danazol-pediatric-drug-information/abstract-text/23282420/pubmed\" target=\"_blank\" id=\"23282420\">23282420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Danazol [prescribing information]. Pulaski, TN: AvKare, Inc; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Danazol [prescribing information]. Sellersville, PA: Teva Pharmaceuticals USA; January 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farkas H, Martinez-Saguer I, Bork K, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. <i>Allergy</i>. 2017;72(2):300-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/danazol-pediatric-drug-information/abstract-text/27503784/pubmed\" target=\"_blank\" id=\"27503784\">27503784</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kishino Y, Tanaka Y, Naitoh S, Kamisako T. Danazol falsely increased values in estradiol immunoassays. <i>Clin Chim Acta</i>. 2010;411(17-18):1380-1381.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/danazol-pediatric-drug-information/abstract-text/20478287/pubmed\" target=\"_blank\" id=\"20478287\">20478287</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. <i>Blood</i>. 2011;117(16):4190-4207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/danazol-pediatric-drug-information/abstract-text/21325604/pubmed\" target=\"_blank\" id=\"21325604\">21325604</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zuraw BL, Banerji A, Bernstein JA, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. <i>J Allergy Clin Immunol Pract</i>. 2013a;1(5):458-467.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/danazol-pediatric-drug-information/abstract-text/24565617/pubmed\" target=\"_blank\" id=\"24565617\">24565617</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zuraw BL, Bernstein JA, Lang DM, et al. A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. <i>J Allergy Clin Immunol</i>. 2013b;131(6):1491-1493.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/danazol-pediatric-drug-information/abstract-text/23726531/pubmed\" target=\"_blank\" id=\"23726531\">23726531</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13199 Version 110.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708691\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F156636\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1057632\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1057624\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F156615\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F156600\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1057635\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F156629\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1057634\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F156684\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F156683\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F156619\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F156604\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F50586771\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F156674\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F156608\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F156630\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F156611\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F156622\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1057631\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F156603\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F156618\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F156621\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F156623\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13199|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=danazol-drug-information\" class=\"drug drug_general\">Danazol: Drug information</a></li><li><a href=\"topic.htm?path=danazol-patient-drug-information\" class=\"drug drug_patient\">Danazol: Patient drug information</a></li></ul></div></div>","javascript":null}